PCSK9 shot: 62% LDL reduction
A single-infusion gene-editing therapy (VRRV-102) targeting the PCSK9 gene reduced LDL cholesterol by 62% and PCSK9 protein levels by 88% in a Phase 1 trial.
Snapshot
From Moonshots with Peter Diamandis · Jun 6, 2026
A single-infusion gene-editing therapy (VRRV-102) targeting the PCSK9 gene reduced LDL cholesterol by 62% and PCSK9 protein levels by 88% in a Phase 1 trial.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.